Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

If you suffered losses exceeding $50,000 in Intellia between July 30, 2024 and January 8, 2025 and would like to discuss your ...

Cantor Fitzgerald issued their FY2025 EPS estimates for Intellia Therapeutics in a research report issued on Monday, March 17th. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Using CRISPR/Cas9 gene-editing technology, Intellia Therapeutics develops gene-editing treatments for genetic diseases. The company's lead programs, NTLA-2001 and NTLA-2002, target transthyretin ...

THE LAWSUIT: A class action securities lawsuit was filed against Intellia Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud ...

Analysts are intrested in these 5 stocks: ( ($PLTR) ), ( ($GOLD) ), ( ($INTU) ), ( ($NTLA) ) and ( ($BYON) ). Here is a breakdown of their recent ...

Intellia Therapeutics details progress in Phase 3 trials for NTLA-2002 and nex-z, anticipating key regulatory submissions by 2026. Intellia Therapeutics has announced the initiation of the global ...

Bank of New York Mellon Corp reduced its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 1.3% in the 4th quarter, according to the company in its most recent 13F ...

CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hund ...